Evaluating the Safety, Tolerability, and Efficacy of GRF312 5% in Participants With Dry Eye Disease (DED).
NCT07264517
·
clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
100
Enrollment
INDUSTRY
Sponsor class
Conditions
Dry Eye Disease
Interventions
DRUG:
GRF312 5%
OTHER:
Placebo Comparator
Sponsor
Instituto Grifols, S.A.